Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that it has received its FY2023 R&D Tax Incentive refund of $1.94 million. These funds further strengthen Arovella’s cash position ($5.3 million at 30 September 2023) as it progresses development of its lead asset, ALA-101, towards first-in-human clinical trials.
CEO and Managing Director, Dr Michael Baker, commented “The R&D Tax Incentive scheme provides valuable support for companies such as Arovella and we look forward to using these funds to advance our programs towards the clinic.”
For more information, download the attached PDF.
Download this document
